Nimodipine

FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Aug. 27, 2025 -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for GTx-104 for formal review. The application seeks approval for GTx-104 for the treatment of patients with aSAH, and is supported by a comprehensive data package including positive data obtained from the Company’s Phase 3 STRIVE-ON safety trial of GTx-104. The FDA established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the Company’s NDA submission. “FDA acceptance for review of our NDA for GTx-104 for the treatment of aSAH is another significant milestone for Grace Therapeutics, further demonstrating our ability to execute as we continue to advance this important innovation for aSAH patients,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “Our NDA is supported by a robust data package including positive results from our STRIVE-ON trial, which provide support for improved clinical outcomes in aSAH patients and both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in the treatment of aSAH. The standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and we believe these results point to a very promising role for GTx-104, if approved, as a potential breakthrough for the care of aSAH patients. We look forward to engaging with the FDA during their review process.” Acceptance of the NDA for review triggers the potential exercise of up to $7.6 million in warrants issued as part of a private placement the Company completed in September 2023. Under the terms of the September 2023 private placement, each warrant is exercisable for one share of common stock at an exercise price of $3.003 per share. These warrants are currently exercisable and will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company's product candidate GTX-104 or (ii) September 25, 2028. Grace has obtained Orphan Drug Designation from the FDA for GTx-104, which generally provides seven years of marketing exclusivity in United States upon FDA approval of the NDA. Additionally, the Company believes that its U.S. and international patent estate will protect the market value of GTx-104 beyond marketing exclusivity. The STRIVE-ON safety trial (NCT05995405) was a prospective, randomized open-label trial of GTx-104 compared with oral nimodipine in patients hospitalized with aSAH. 50 patients were administered GTx-104 and 52 patients received oral nimodipine. The primary endpoint was the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug, and additional secondary endpoints included safety, clinical, and pharmacoeconomic outcomes. The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine (28% versus 35%). Other measures also favored or were comparable to GTx-104, including: 54% patients receiving GTx-104 had relative dose intensity (RDI) of 95% or higher compared to only 8% on oral nimodipine, and 29% more patients receiving GTx-104 had favorable functional outcomes at 90 days compared to oral nimodipine. In addition, there were fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine. Adverse events were comparable between the two arms and no new safety issues were identified with patients receiving GTx-104. All deaths in both arms of the trial were due to severity of the patient’s underlying disease. There were eight deaths on the GTx-104 arm compared to four deaths on the oral nimodipine arm. The survival status of one patient on the oral nimodipine arm was unknown. No deaths were determined to be related to GTx-104 or oral nimodipine. aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients. GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine. Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The content above comes from the network. if any infringement, please contact us to modify.

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CYHB2401772对乙酰氨基酚片华中药业股份有限公司————2025年08月13日2CYHB2401976阿莫西林克拉维酸钾片山西同达药业有限公司————2025年08月13日3CYHB2401977阿莫西林克拉维酸钾片山西同达药业有限公司————2025年08月13日4CYHB2450423己酮可可碱注射液山东方明药业集团股份有限公司————2025年08月13日5CYHB2501465尼莫地平口服溶液浙江核力欣健药业有限公司————2025年08月13日6CYHB2501466缩宫素注射液云南药科院生物医药股份有限公司————2025年08月13日7CYHB2501469盐酸特比萘芬乳膏广东香山堂制药有限公司————2025年08月13日8CYHB2501488大黄碳酸氢钠片广东三顺制药有限公司————2025年08月13日9CYHB2501497复方倍氯米松樟脑乳膏上海延安医药洋浦股份有限公司————2025年08月13日10CYHB2501509氨咖黄敏胶囊广西金海堂药业有限责任公司————2025年08月13日11CYSB2500124贝伐珠单抗注射液齐鲁制药有限公司————2025年08月13日12JYHB2500251注射用双羟萘酸曲普瑞林益普生（天津）医药商贸有限公司————2025年08月13日13JYHB2500252注射用醋酸曲普瑞林益普生（天津）医药商贸有限公司————2025年08月13日14JYHB2500279奥拉帕利片阿斯利康投资（中国）有限公司————2025年08月13日15JYHB2500280奥拉帕利片阿斯利康投资（中国）有限公司————2025年08月13日16JYHB2500387卤米松/三氯生乳膏诺思格（北京）医药科技股份有限公司————2025年08月13日17JYHZ2500088匹伐他汀钙片兴和制药（中国）有限公司国药准字HJ201404172025年08月13日18JYHZ2500089匹伐他汀钙片兴和制药（中国）有限公司国药准字HJ201409372025年08月13日19JYHZ2500090匹伐他汀钙片兴和制药（中国）有限公司国药准字HJ201401012025年08月13日20JYHZ2500091匹伐他汀钙片兴和制药（中国）有限公司国药准字HJ201812462025年08月13日21JYHZ2500092匹伐他汀钙片兴和制药（中国）有限公司国药准字HJ201404162025年08月13日